The contemporary practice of medicine stands at a pivotal crossroads in which the long dominant paradigm of evidence based medicine built primarily upon randomized controlled trials is being challenged by the growing availability, sophistication, and regulatory acceptance of real world data and real world evidence. This shift is not merely technical but epistemological, redefining what counts as valid knowledge, how uncertainty is handled, and how healthcare decisions are made in complex real life clinical environments. Evidence based medicine emerged as a corrective to intuition driven and authority based practice, yet over time it has faced increasing criticism for privileging methodological purity over clinical relevance, for excluding patients with comorbidities, and for producing results that are often difficult to translate into everyday care. Real world evidence has risen in response to these limitations, offering insights derived from routine clinical practice, electronic health records, insurance claims, registries, and patient reported outcomes. This article develops a comprehensive theoretical and empirical analysis of how real world evidence is reshaping evidence based medicine across clinical, regulatory, and payer decision making contexts. Drawing strictly on the provided references, it explores the philosophical crisis of evidence based medicine, the conceptual foundations of real world data, the evolving regulatory landscape in the United States, Japan, and other advanced systems, and the methodological innovations that enable observational data to approach causal inference. The article also examines pragmatic trials, propensity score methods, and hybrid designs that integrate randomized and observational approaches. Particular attention is given to the external validity problem, which arises when trial populations fail to represent the diversity of real patients, and how real world evidence provides a corrective by capturing heterogeneity, comorbidity, and long term outcomes. The analysis further addresses concerns regarding bias, data quality, and reproducibility, and demonstrates how quality standards, regulatory frameworks, and advanced analytic techniques are being developed to ensure that real world evidence complements rather than undermines scientific rigor. The article concludes that the future of evidence based medicine lies not in abandoning randomized trials but in integrating them within a broader evidence ecosystem in which real world evidence plays an essential and increasingly authoritative role.